We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $118M
This Fund
S&P 500
This Quarter Est. Return
+1.03%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$207M
AUM Growth
+$29.2M
Cap. Flow
+$27.6M
Cap. Flow %
13.39%
Top 10 Hldgs %
88.47%
Holding
181
New
37
Increased
23
Reduced
71
Closed
16

Top Buys

Rank Stock Value
1
MBB icon
iShares MBS ETF
MBB
+$27.6M
2
BKLN icon
Invesco Senior Loan ETF
BKLN
+$319K
3
EMHY icon
iShares JPMorgan EM High Yield Bond ETF
EMHY
+$309K
4
SHYG icon
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
+$249K
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$228K

Top Sells

Rank Stock Value
1
SHY icon
iShares 1-3 Year Treasury Bond ETF
SHY
+$2.55M
2
NNDM
Nano Dimension
NNDM
+$330K
3
BTAI icon
BioXcel Therapeutics
BTAI
+$235K
4
NUAN
Nuance Communications, Inc.
NUAN
+$145K
5
KTOS icon
Kratos Defense & Security Solutions
KTOS
+$92.4K

Sector Composition

Rank Sector Weight
1 Real Estate 17.29%
2 Healthcare 5.02%
3 Technology 2.17%
4 Industrials 1.56%
5 Financials 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
151
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$14K 0.01%
+550
New +$12.5K
IFRX icon
152
InflaRx
IFRX
$256M
$13K 0.01%
+3,000
New +$13.8K
MRTX
153
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$13K 0.01%
80
-120
-60% -$16.4K
APLS
154
DELISTED
Apellis Pharmaceuticals
APLS
$12K 0.01%
+400
New +$12K
ORTX
155
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$12K 0.01%
290
-70
-19% -$3.62K
ARGX icon
156
argenx
ARGX
$57.4B
$11K 0.01%
40
-10
-20% -$2.4K
RCKT icon
157
Rocket Pharmaceuticals
RCKT
$348M
$10K ﹤0.01%
450
-50
-10% -$1.23K
BIIB icon
158
Biogen
BIIB
$29.9B
$9K ﹤0.01%
30
-90
-75% -$25.1K
GSK icon
159
GSK
GSK
$103B
$8K ﹤0.01%
160
– –
TRIL
160
DELISTED
Trillium Therapeutics Inc.
TRIL
$7K ﹤0.01%
500
– –
XNCR icon
161
Xencor
XNCR
$1.44B
$4K ﹤0.01%
+100
New +$3.47K
DVAX
162
DELISTED
Dynavax Technologies
DVAX
$3K ﹤0.01%
600
+300
+100% +$2.14K
VRTX icon
163
Vertex Pharmaceuticals
VRTX
$121B
$3K ﹤0.01%
10
– –
ALXO icon
164
ALX Oncology
ALXO
$273M
$2K ﹤0.01%
+50
New +$1.97K
AERI
165
DELISTED
Aerie Pharmaceuticals
AERI
$1K ﹤0.01%
+100
New +$1.22K
AVDL
166
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-2,500
Closed -$20K
BLUE
167
DELISTED
bluebird bio
BLUE
– –
-12
Closed -$9K
BNTX icon
168
BioNTech
BNTX
$22.6B
– –
-550
Closed -$37K
CI icon
169
Cigna
CI
$76.6B
– –
-65
Closed -$12K
ELV icon
170
Elevance Health
ELV
$81.9B
– –
-35
Closed -$9K
MMIN icon
171
IQ MacKay Municipal Insured ETF
MMIN
$463M
– –
-925
Closed -$25K
NNDM
172
Nano Dimension
NNDM
$309M
– –
-150,000
Closed -$330K
NVS icon
173
Novartis
NVS
$295B
– –
-550
Closed -$48K
PFE icon
174
Pfizer
PFE
$140B
– –
-211
Closed -$7K
SNDX icon
175
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-200
Closed -$3K
4 5 6
7
8

Similar funds

AIS
Advocate Investing Services Woodbine, Maryland $118M AUM
IVGAI
Index Venture Growth Associates III St. Helier, Channel Islands, Jersey $118M AUM 64.91% 1-Year Est. Return
OIM
Oceanic Investment Management Douglas, Isle Of Man $118M AUM
TIP
Tandem Investment Partners Bordentown, New Jersey $118M AUM 15.76% 1-Year Est. Return
RCG
Ridge Creek Global Strongsville, Ohio $118M AUM
CWM
Capstone Wealth Management Billings, Montana $118M AUM
SPW
Stillwater Private Wealth Glen Mills, Pennsylvania $118M AUM
WLC
Walnut Level Capital Denver, Colorado $118M AUM 59.12% 1-Year Est. Return

AlphaCentric Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, AlphaCentric Advisors held 181 positions worth $207M, up 16% from $177M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

AlphaCentric Advisors deployed $27.6M of net new capital in Q3 2020, opening 37 new positions and adding to 23 existing holdings. Its largest new stake was iShares JPMorgan EM High Yield Bond ETF: 6,992 shares worth $305K.

By sector, the portfolio is most concentrated in Real Estate at 17% of assets, down from 19% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was iShares 1-3 Year Treasury Bond ETF, an estimated $2.55M trimmed.

  • AlphaCentric Advisors's largest Q3 2020 buy was iShares JPMorgan EM High Yield Bond ETF: 6,992 shares worth $305K.
  • AlphaCentric Advisors added most to iShares MBS ETF in Q3 2020, an estimated $27.6M increase.
  • AlphaCentric Advisors's biggest Q3 2020 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $2.55M.
  • AlphaCentric Advisors fully exited Nano Dimension in Q3 2020, selling an estimated $330K.
  • AlphaCentric Advisors's ten largest holdings make up 88% of its $207M portfolio in Q3 2020.
  • AlphaCentric Advisors opened 37 new positions and closed 16 in Q3 2020.
  • AlphaCentric Advisors's portfolio value rose 16% quarter-over-quarter to $207M.

Based on AlphaCentric Advisors's 13F filing for Q3 2020, filed 11 Mar 2022.